Cargando…
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Background: The PI3K/Akt/mTOR pathway in part impacts tumorigenesis through modulation of host immune activity. To assess the effects of Akt inhibition on the tumor micro-environment (TME), we analyzed tumor tissue from patients with operable hormone receptor positive, HER2 negative breast cancer (B...
Autores principales: | Marks, Douglas K., Gartrell, Robyn D., El Asmar, Margueritta, Boboila, Shuobo, Hart, Thomas, Lu, Yan, Pan, Qingfei, Yu, Jiyang, Hibshoosh, Hanina, Guo, Hua, Andreopoulou, Eleni, Wiechmann, Lisa, Crew, Katherine, Sparano, Joseph, Hershman, Dawn, Connolly, Eileen, Saenger, Yvonne, Kalinsky, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308467/ https://www.ncbi.nlm.nih.gov/pubmed/32612958 http://dx.doi.org/10.3389/fonc.2020.00968 |
Ejemplares similares
-
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography
por: Altoe, Mirella L., et al.
Publicado: (2021) -
Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma
por: Boboila, Shuobo, et al.
Publicado: (2023) -
Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients
por: Baer, Lea N, et al.
Publicado: (2014) -
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
por: Kearney, Matthew, et al.
Publicado: (2021) -
Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma
por: Boboila, Shuobo, et al.
Publicado: (2018)